HL-2351

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameHL-2351
Drug Alias NameGX-P4-GenexineRecombinant human interleukin-1 receptor antagonist hybrid FcrhIL-1Ra-hyFcHL-2351GX-P4
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-6 inhibitorsInterleukin-8 inhibitorsInterleukin-1 receptor antagonists
TargetsInterleukin-6Interleukin-1 receptorInterleukin-8
Therapy Area/IndicationsCryopyrin-Associated Periodic Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGannex Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHandok Inc
Active IndicationsN/A
Inactive IndicationsCryopyrin-Associated Periodic Syndromes

Other Information

ATC CodeN/A
Related LinksN/A